Kenneth Hande
Faculty Member
Last active: 3/20/2014

Profile

None provided

Publications

The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Bone cancer. Biermann JS, Adkins DR, Agulnik M, Benjamin RS, Brigman B, Butrynski JE, Cheong D, Chow W, Curry WT, Frassica DA, Frassica FJ, Hande KR, Hornicek FJ, Jones RL, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, von Mehren M, Bergman MA, Sundar H, National complrehensive cancer network (2013) J Natl Compr Canc Netw 11(6): 688-723
    › Primary publication · 23744868 (PubMed)
  2. Signal transduction pathway analysis in desmoid-type fibromatosis: transforming growth factor-β, COX2 and sex steroid receptors. Mignemi NA, Itani DM, Fasig JH, Keedy VL, Hande KR, Whited BW, Homlar KC, Correa H, Coffin CM, Black JO, Yi Y, Halpern JL, Holt GE, Schwartz HS, Schoenecker JG, Cates JM (2012) Cancer Sci 103(12): 2173-80
    › Primary publication · 23035734 (PubMed) · PMC4278584 (PubMed Central)
  3. Nuclear p63 expression in osteoblastic tumors. Kallen ME, Sanders ME, Gonzalez AL, Black JO, Keedy VL, Hande KR, Homlar KC, Halpern JL, Holt GE, Schwartz HS, Coffin CM, Cates JM (2012) Tumour Biol 33(5): 1639-44
    › Primary publication · 22623071 (PubMed)
  4. Signal transduction pathway analysis in fibromatosis: receptor and nonreceptor tyrosine kinases. Cates JM, Black JO, Itani DM, Fasig JH, Keedy VL, Hande KR, Whited BW, Homlar KC, Halpern JL, Holt GE, Schwartz HS, Coffin CM (2012) Hum Pathol 43(10): 1711-8
    › Primary publication · 22520949 (PubMed) · PMC4278590 (PubMed Central)
  5. Morphologic and immunophenotypic analysis of desmoid-type fibromatosis after radiation therapy. Cates JM, Black J, Wolfe CC, Shinohara ET, Holt GE, Keedy VL, Hande KR, Homlar KC, Halpern JL, Schwartz HS, Troutman A, Coffin CM (2012) Hum Pathol 43(9): 1418-24
    › Primary publication · 22404950 (PubMed)
  6. Bone cancer. Biermann JS, Adkins DR, Benjamin RS, Brigman B, Chow W, Conrad EU, Frassica DA, Frassica FJ, George S, Hande KR, Hornicek FJ, Letson GD, Mayerson J, McGarry SV, McGrath B, Morris CD, O'Donnell RJ, Randall RL, Santana VM, Satcher RL, Siegel HJ, Somaiah N, Yasko AW, National Comprehensive Cancer Network Bone Cancer Panel (2010) J Natl Compr Canc Netw 8(6): 688-712
    › Primary publication · 20581300 (PubMed)
  7. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A (2009) J Clin Oncol 27(25): 4188-96
    › Primary publication · 19652065 (PubMed)
  8. Developing an in-training examination for fellows: the experience of the American Society of Clinical Oncology. Collichio FA, Kayoumi KM, Hande KR, Hawkins RE, Hawley JL, Adelstein DJ, D'Angelo JM, Stewart JA (2009) J Clin Oncol 27(10): 1706-11
    › Primary publication · 19224843 (PubMed)
  9. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, Lockhart AC, Medina D, Sosman J, Gordon GB, Rothenberg ML (2006) Clin Cancer Res 12(9): 2834-40
    › Primary publication · 16675578 (PubMed)
  10. Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer. Lockhart AC, Cropp GF, Berlin JD, Donnelly E, Schumaker RD, Schaaf LJ, Hande KR, Fleischer AC, Hannah AL, Rothenberg ML (2006) Am J Clin Oncol 29(2): 109-15
    › Primary publication · 16601426 (PubMed)
  11. Topoisomerase II inhibitors. Martincic D, Hande KR (2005) Cancer Chemother Biol Response Modif : 101-21
    › Primary publication · 16110609 (PubMed)
  12. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Nygren P, Hande K, Petty KJ, Fedgchin M, van Dyck K, Majumdar A, Panebianco D, de Smet M, Ahmed T, Murphy MG, Gottesdiener KM, Cocquyt V, van Belle S (2005) Cancer Chemother Pharmacol 55(6): 609-16
    › Primary publication · 15723220 (PubMed)
  13. Topoisomerase II inhibitors. Hande KR (2003) Cancer Chemother Biol Response Modif : 103-25
    › Primary publication · 15338742 (PubMed)